David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

Despite Its Recent Hard Landing, Stay on Board With Virgin Galactic Stock

By David Moadel, InvestorPlace Contributor

SPCE stock skeptics had a field day when Virgin Galactic's test flight failed, but look closer and you'll see signs of positive developments.

Crypto Exchange Delistings Could Spell Trouble for Zcash

By David Moadel, InvestorPlace Contributor

Some folks might say that privacy coins are the future of money. That might be true, but lately Zcash has seemingly been under siege.

Don’t Get Shaken Out by Bitcoin’s Wild Ride

By David Moadel, InvestorPlace Contributor

Traders should understand that cryptocurrencies don't trade like blue-chip stocks. So if you're investing in bitcoin, prepare for volatility.

Don’t Write Off the ContextLogic-Wish IPO As a Flop

By David Moadel, InvestorPlace Contributor

While not necessariliy off to a great start like some other IPO's, WISH stock could be an outstanding e-commerce play in 2021.

Expect This Pullback in High-Flying Zomedica Pharmaceuticals Stock to Continue

By David Moadel, InvestorPlace Contributor

Even with the company addressing a potentially hyper-growth market, the price action of ZOM stock is just too frothy.

Load More